The most common driver is sponsor program shifts. When a pharmaceutical company makes a strategic decision — kill a development program, pivot to a new indication, consolidate after an acquisition — the downstream effect at the investigator site is a wave of closures. Three studies under the same sponsor may all receive close-out notifications within the same month. The RC did not cause this. The RC cannot control it. But the RC must manage it.

Therapeutic area timelines create another clustering pattern. Oncology trials at a site often share enrollment timelines because they draw from overlapping patient populations and similar referral networks. When enrollment completes on one, the others are not far behind. Cardiology trials pegged to the same seasonal enrollment patterns may complete within weeks of each other. And the end of a fiscal year — when sponsors review their portfolios and make go/no-go decisions — reliably generates a fourth-quarter closure spike that experienced RCs know to expect by October.

The problem is not the closures themselves. Lesson 1 of this module established the checklist and sequencing that makes each individual close-out manageable. The problem is what closures do to everything else. Three simultaneous close-outs, each requiring final report preparation, three-stakeholder notifications, monitoring visit coordination, and verification steps, will consume 40 to 60 hours of combined RC and CRC time over four to six weeks. That time does not materialize from nowhere. It is taken from the ongoing portfolio — the continuing reviews still due on schedule, the amendments still arriving from sponsors, the new study start-up that cannot wait because the sponsor's enrollment timeline has already begun.

This is the bandwidth trap. And it is, in my assessment, one of the most underdiscussed risks in portfolio management.

The most common driver is sponsor program shifts. When a pharmaceutical company makes a strategic decision — kill a development program, pivot to a new indication, consolidate after an acquisition — the downstream effect at the investigator site is a wave of closures. Three studies under the same sponsor may all receive close-out notifications within the same month. The RC did not cause this. The RC cannot control it. But the RC must manage it.

Therapeutic area timelines create another clustering pattern. Oncology trials at a site often share enrollment timelines because they draw from overlapping patient populations and similar referral networks. When enrollment completes on one, the others are not far behind. Cardiology trials pegged to the same seasonal enrollment patterns may complete within weeks of each other. And the end of a fiscal year — when sponsors review their portfolios and make go/no-go decisions — reliably generates a fourth-quarter closure spike that experienced RCs know to expect by October.

The problem is not the closures themselves. Lesson 1 of this module established the checklist and sequencing that makes each individual close-out manageable. The problem is what closures do to everything else. Three simultaneous close-outs, each requiring final report preparation, three-stakeholder notifications, monitoring visit coordination, and verification steps, will consume 40 to 60 hours of combined RC and CRC time over four to six weeks. That time does not materialize from nowhere. It is taken from the ongoing portfolio — the continuing reviews still due on schedule, the amendments still arriving from sponsors, the new study start-up that cannot wait because the sponsor's enrollment timeline has already begun.

This is the bandwidth trap. And it is, in my assessment, one of the most underdiscussed risks in portfolio management.